CAAS
INMB icon

Capital Asset Advisory Services’s INmune Bio INMB Stock Holding History

Capital Asset Advisory Services’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,875
Closed -$32K – 1062
2020
Q4 		$32K Buy
+1,875
New +$17.7K 0.01% 720

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Capital Asset Advisory Services's INMB Position: Q1 2021 in Review

Capital Asset Advisory Services sold out of INmune Bio (INMB) in Q1 2021, closing a stake of 1,875 shares — an estimated $32K sold.

Capital Asset Advisory Services first reported a position in INMB in Q4 2020 and held it in 1 quarter. The position peaked at $32K in Q4 2020. 33 funds tracked by Wall St. Rank hold INMB as of Q1 2021.

  • Capital Asset Advisory Services reported no remaining INmune Bio position as of Q1 2021 after selling out during the quarter.
  • Capital Asset Advisory Services sold 1,875 INmune Bio shares in Q1 2021, an estimated $32K.
  • Capital Asset Advisory Services first reported a position in INmune Bio in Q4 2020 and held it in 1 quarter.
  • Capital Asset Advisory Services's INmune Bio position peaked at $32K in Q4 2020.
  • 33 funds tracked by Wall St. Rank held INmune Bio as of Q1 2021.

Based on Capital Asset Advisory Services's 13F filing for Q1 2021, filed 13 May 2021.